We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




PCR-Based Blood Test Accurately Diagnoses Active Tuberculosis

By LabMedica International staff writers
Posted on 06 Mar 2016
A panel of three genes has been established that accurately distinguishes individuals with active tuberculosis (TB) from healthy individuals or from patients with chronic TB or AIDS.

Active pulmonary tuberculosis is difficult to diagnose and treatment response is difficult to monitor effectively. More...
In response to a World Health Organization (WHO) call for new non-sputum diagnostics, investigators at Stanford University (Palo Alto, CA, USA) developed a simple, PCR-based assay to test for active TB in samples of patients' blood.

The investigators screened a total of 14 datasets containing 2,572 samples from 10 countries from both adult and pediatric patients. Of these, three datasets comprising 1,023 samples were used to discover a set of three genes (GBP5, DUSP3, and KLF2) that were highly diagnostic for active tuberculosis.

The diagnostic power of the three gene set to separate active tuberculosis from healthy controls, latent tuberculosis, and other diseases was validated in eight independent datasets composed of both children and adults from ten countries. The assay was shown to be 86% sensitive and 99% in children.

Expression of the three-gene set was not masked by HIV infection status, bacterial drug resistance, or BCG vaccination. Furthermore, in four additional cohorts, the investigators showed that the tuberculosis score declined during treatment of patients with active tuberculosis.

"One-third of the world's population is currently infected with TB. Even if only 10% of them get active TB, that is still 3% of the world's population—240 million people," said senior author Dr. Purvesh Khatri, assistant professor of medicine at Stanford University.

The study was published in the February 19, 2016, online edition of the journal Lancet Respiratory Medicine.

Related Links:

Stanford University



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Blood Glucose Reference Analyzer
Nova Primary
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.